How to Prescribe and Titrate Repaglinide 0.5mg
Start repaglinide 0.5 mg orally within 30 minutes before each meal (2-4 times daily depending on meal pattern), then double the dose weekly up to 4 mg per meal until glycemic targets are achieved, with a maximum daily dose of 16 mg. 11
Initial Dosing Strategy
The 0.5 mg starting dose is specifically indicated for patients with HbA1c <8%. If HbA1c is ≥8%, consider starting at 1-2 mg per meal instead 1. However, the 0.5 mg dose is also the mandatory starting dose for:
- Severe renal impairment (CrCl 20-40 mL/min) 1
- Concomitant use with clopidogrel (if unavoidable; max 4 mg total daily dose) 1
- Patients at higher risk for hypoglycemia
Titration Protocol
The systematic approach:
- Frequency: Administer before each meal (2-4 times daily based on actual meal pattern)
- Timing: Within 30 minutes before eating 11
- Dose escalation: Double the dose at each meal (0.5 mg → 1 mg → 2 mg → 4 mg per meal)
- Assessment interval: Wait at least one week between dose adjustments to evaluate response 1
- Target: Continue titration until satisfactory glycemic control is achieved
- Maximum: 4 mg per meal, 16 mg total daily dose 11
Research supports that titration based on fasting blood glucose monitoring (target 4.4-6.1 mmol/L or 79-110 mg/dL) produces superior HbA1c reduction compared to postprandial monitoring, though it requires higher doses and more careful monitoring 2.
Critical Meal-Skipping Rule
If the patient skips a meal, they must skip that dose of repaglinide to prevent hypoglycemia 11. This is non-negotiable and distinguishes repaglinide from sulfonylureas. The flexible dosing (2-4 times daily) should match the patient's actual eating pattern.
Special Populations and Drug Interactions
Absolute contraindications:
- Gemfibrozil (contraindicated) 1
Dose restrictions:
- Cyclosporine: Maximum 6 mg total daily dose 1
- Clopidogrel: Start 0.5 mg, maximum 4 mg total daily dose 1
- Severe renal impairment: Start 0.5 mg, titrate gradually 1
Be vigilant for CYP3A4 and CYP2C8 inhibitors (e.g., nilotinib, febuxostat) which can dramatically prolong repaglinide elimination and cause severe hypoglycemia even at low doses 3.
Monitoring for Hypoglycemia
Hypoglycemia is the primary safety concern. Risk factors include:
- Skipped meals without skipping dose
- Changes in meal pattern or macronutrient content
- Increased physical activity
- Renal or hepatic impairment
- Drug interactions 1
If hypoglycemia occurs, reduce the dose immediately 11. Clinical trials show hypoglycemia rates of 15-20%, similar to sulfonylureas, but typically mild and occurring during titration 456.
Context Within Current Guidelines
While repaglinide effectively lowers glucose, current 2025 ADA guidelines prioritize GLP-1 RAs and SGLT2 inhibitors for most patients with type 2 diabetes due to cardiovascular and renal benefits 78. Repaglinide (a meglitinide) carries hypoglycemia risk and should be reassessed when initiating newer agents 7. The guidelines specifically recommend reducing or discontinuing medications with hypoglycemia risk (including meglitinides) when adding GLP-1 RAs or other agents 7.
Repaglinide is most appropriate for:
- Patients who cannot tolerate or access preferred agents
- Those requiring flexible meal-based dosing
- Patients with severe renal impairment where other options are limited (though GLP-1 RAs are now preferred even in advanced CKD) 7
Practical Titration Example
Week 0: 0.5 mg before breakfast, lunch, dinner (1.5 mg/day)
Week 1: Assess fasting glucose; if >110 mg/dL, increase to 1 mg per meal (3 mg/day)
Week 2: If still above target, increase to 2 mg per meal (6 mg/day)
Week 3: If needed, increase to 4 mg per meal (12 mg/day)
Adjust meal frequency dosing based on patient's actual eating pattern—if they only eat twice daily, dose twice daily.